UK's Cambridge Nutritional Sciences H1 revenue falls 39% on weak China demand

By Reuters News


Overview

  • UK medical diagnostics firm's H1 revenue fell 39% yr/yr amid lower orders in most regions

  • Adjusted EBITDA swung to a loss from a profit a year ago

  • Gross margin slipped to 66.4% from 67.7% due to lower sales


Outlook

  • Company still expects full-year sales to be lower than previous yr due to market headwinds

  • Policy changes in China expected to disrupt demand for several years

  • Company expects H2 adjusted EBITDA near breakeven and gross margins to hold


Result Drivers

  • WEAK DEMAND - Co said global economic pressures reduced consumer willingness to spend on premium tests, leading to lower orders in many markets

  • REGIONAL WEAKNESS - Lower orders in Asia, especially China, Thailand, Korea and Indonesia, were main contributors to revenue decline

  • COST CUTTING - Co reduced administration costs by £0.5m yr/yr through restructuring efforts


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Gross Margin

66.40%

H1 Revenue

£2.4 mln


Analyst Coverage

  • The one available analyst rating on the shares is "strong buy"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Cambridge Nutritional Sciences PLC is GBp3.00, about 93.5% above its November 9 closing price of GBp1.55


Reuters Recommended Reads

  • Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations

  • Nov 9 - UK's Kainos Group H1 revenue rises 37% on public sector contracts

  • Nov 9 - German exports rise more than expected in September


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.